Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A11 | P48066 | 4/20 | 0.43 |
| ▸ | SLC6A1 | P30531 | 2/20 | 0.43 |
| ▸ | KIF11 | P52732 | 8/20 | 0.40 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | SLC6A12 | P48065 | 1/20 | 0.38 |
| ▸ | SLC6A13 | Q9NSD5 | 1/20 | 0.38 |
| ▸ | TK2 | O00142 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6040158 | 0.90 | SLC6A11 (0.46) | SLC6A11SLC6A1KIF11KCNH2MEN1 | |
| SCHEMBL13575115 | 0.90 | SLC6A11 (0.46) | SLC6A11SLC6A1KIF11KCNH2MEN1 | |
| SCHEMBL2385290 | 0.90 | SLC6A11 (0.46) | SLC6A11SLC6A1KIF11KCNH2MEN1 | |
| SCHEMBL2400336 | 0.90 | SLC6A11 (0.46) | SLC6A11SLC6A1KIF11KCNH2MEN1 | |
| SCHEMBL6570212 | 0.87 | SLC6A11 (0.47) | SLC6A11SLC6A1KIF11KCNH2MEN1 | |
| SCHEMBL2288429 | 0.84 | NR3C2 (0.33) | SLC6A1KIF11TK2 | |
| SCHEMBL12582832 | 0.83 | KIF11 (0.42) | SLC6A11SLC6A1KIF11KCNH2MEN1 | |
| SCHEMBL8327519 | 0.83 | KIF11 (0.42) | SLC6A11SLC6A1KIF11KCNH2MEN1 | |
| SCHEMBL16021678 | 0.82 | KIF11 (0.46) | SLC6A11SLC6A1KIF11KCNH2MEN1 | |
| SCHEMBL7165376 | 0.82 | KIF11 (0.46) | SLC6A11SLC6A1KIF11KCNH2MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2011097092-A2 | SOLID-SUPPORTED ETHER DISULFIDES | BERRY AND ASSOCIATES, INC. (US) | 2011-08-11 | — | — | WO | disclosed |
| US-20110190485-A1 | SOLID-SUPPORTED ETHER DISULFIDES | BERRY AND ASSOCIATES, INC. (US) | 2011-08-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110190485-A1 | SOLID-SUPPORTED ETHER DISULFIDES | NSUN3, NSUN2, SNRPA1 | SLC6A11 3021/4885SLC6A1 3312/4885KIF11 1984/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.